Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Camp4 Therapeutics (CAMP) EBIT Margin (2023 - 2025)

Camp4 Therapeutics' EBIT Margin history spans 3 years, with the latest figure at 3671.26% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 151866.0% year-over-year to 3671.26%; the TTM value through Dec 2025 reached 1502.43%, up 663990.0%, while the annual FY2025 figure was 1502.43%, 663990.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 3671.26% at Camp4 Therapeutics, down from 1717.11% in the prior quarter.
  • Across five years, EBIT Margin topped out at 16236.14% in Q4 2023 and bottomed at 3671.26% in Q4 2025.
  • The 3-year median for EBIT Margin is 1621.96% (2025), against an average of 1049.68%.
  • The largest annual shift saw EBIT Margin plummeted -1838875bps in 2024 before it crashed -151866bps in 2025.
  • A 3-year view of EBIT Margin shows it stood at 16236.14% in 2023, then crashed by -113bps to 2152.61% in 2024, then tumbled by -71bps to 3671.26% in 2025.
  • Per Business Quant, the three most recent readings for CAMP's EBIT Margin are 3671.26% (Q4 2025), 1717.11% (Q3 2025), and 870.27% (Q2 2025).